- Home
- RLX vs AXSM Comparison
RLX vs AXSM Comparison
Compare RLX & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLX
- AXSM
- Stock Information
- Founded
- RLX 2018
- AXSM 2012
- Country
- RLX China
- AXSM United States
- Employees
- RLX N/A
- AXSM N/A
- Industry
- RLX Medicinal Chemicals and Botanical Products
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- RLX Health Care
- AXSM Health Care
- Exchange
- RLX Nasdaq
- AXSM Nasdaq
- Market Cap
- RLX 3.7B
- AXSM 4.2B
- IPO Year
- RLX 2021
- AXSM 2015
- Fundamental
- Price
- RLX $2.43
- AXSM $137.75
- Analyst Decision
- RLX Strong Buy
- AXSM Strong Buy
- Analyst Count
- RLX 1
- AXSM 14
- Target Price
- RLX $2.76
- AXSM $158.93
- AVG Volume (30 Days)
- RLX 4.8M
- AXSM 1.1M
- Earning Date
- RLX 03-14-2025
- AXSM 02-18-2025
- Dividend Yield
- RLX 0.33%
- AXSM N/A
- EPS Growth
- RLX 607.62
- AXSM N/A
- EPS
- RLX 0.07
- AXSM N/A
- Revenue
- RLX $307,798,132.00
- AXSM $385,693,000.00
- Revenue This Year
- RLX $117.52
- AXSM $45.18
- Revenue Next Year
- RLX $42.76
- AXSM $65.22
- P/E Ratio
- RLX $32.89
- AXSM N/A
- Revenue Growth
- RLX 99.79
- AXSM 42.53
- 52 Week Low
- RLX $1.50
- AXSM $64.11
- 52 Week High
- RLX $2.69
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- RLX 63.09
- AXSM 74.55
- Support Level
- RLX $2.29
- AXSM $124.04
- Resistance Level
- RLX $2.45
- AXSM $130.52
- Average True Range (ATR)
- RLX 0.12
- AXSM 5.78
- MACD
- RLX -0.00
- AXSM 1.11
- Stochastic Oscillator
- RLX 50.00
- AXSM 96.07
About RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.